scholarly journals Chelation-therapy heart trial draws fire

Nature ◽  
2012 ◽  
Vol 491 (7424) ◽  
pp. 313-315 ◽  
Author(s):  
Ewen Callaway
Keyword(s):  
Chelation Therapy

Therapeutic Macromolecular Iron Chelators

2019 ◽  
Vol 26 (2) ◽  
pp. 323-334 ◽  
Author(s):  
Upendra Bulbake ◽  
Alka Singh ◽  
Abraham J. Domb ◽  
Wahid Khan
Keyword(s):  
Iron Overload ◽  
Chelation Therapy ◽  
Iron Chelator ◽  
Therapeutic Agents ◽  
Iron Chelators ◽  
Low Molecular Weight ◽  
Research Findings ◽  
Pharmaceutical Properties ◽  
Single Living ◽  
Living Process

Iron is a key element for every single living process. On a fundamental level, targeting iron is a valuable approach for the treatment of disorders caused by iron overload. Utilizing iron chelators as therapeutic agents has received expanding consideration in chelation therapy. Approved low molecular weight (MW) iron chelators to treat iron overload may experience short half-lives and toxicities prompting moderately high adverse effects. In recent years, polymeric/macromolecular iron chelators have received attention as therapeutic agents. Polymeric iron chelators show unique pharmaceutical properties that are different to their conventional small molecule counterparts. These polymeric iron chelators possess longer plasma half-lives and reduced toxicities, thus exhibiting a significant supplement to currently using low MW iron chelator therapy. In this review, we have briefly discussed polymeric iron chelators and factors to be considered when designing clinically valuable iron chelators. We have also discussed applications of polymeric iron chelators in the diseases caused by iron overload associated with transfusional hemosiderosis, neurodegenerative disorders, malaria and cancer. With this, research findings for new polymeric iron chelators are also covered.

Iron Chelation Therapy in CAPD: A New and Effective Treatment of Iron Overload Disease in Esrd Patients

1983 ◽  
Vol 3 (2) ◽  
pp. 99-101 ◽  
Author(s):  
Glen H Stanbaugh ◽  
A. W, Holmes Diane Gillit ◽  
George W. Reichel ◽  
Mark Stranz
Keyword(s):  
Peritoneal Dialysis ◽  
Iron Overload ◽  
End Stage Renal Disease ◽  
Chelation Therapy ◽  
Iron Chelation ◽  
Iron Chelation Therapy ◽  
Peritoneal Dialysate ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

A patient with end-stage renal disease on CAPD, and with massive iron overload is reported. This patient had evidence of myocardial and hepatic damage probably as a result of iron overload. Treatment with desferoxamine resulted in removal of iron in the peritoneal dialysate. On the basis of preliminary studies in this patient it would appear that removal of iron by peritoneal dialysis in conjunction with chelation therapy is safe and effective. This finding should have wide-ranging signficance for patients with ESRD.

scholarly journals Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator

Molecules ◽  
2021 ◽  
Vol 26 (11) ◽  
pp. 3255
Author(s):  
Denise Bellotti ◽  
Maurizio Remelli
Keyword(s):  
Metal Ions ◽  
Metal Binding ◽  
Chelation Therapy ◽  
Iron Chelation ◽  
Binding Ability ◽  
Complex Formation Equilibria ◽  
Metal Chelator ◽  
The Past ◽  
Formation Equilibria ◽  
Terminal Amino

Deferoxamine B is an outstanding molecule which has been widely studied in the past decade for its ability to bind iron and many other metal ions. The versatility of this metal chelator makes it suitable for a number of medicinal and analytical applications, from the well-known iron chelation therapy to the most recent use in sensor devices. The three bidentate hydroxamic functional groups of deferoxamine B are the centerpiece of its metal binding ability, which allows the formation of stable complexes with many transition, lanthanoid and actinoid metal ions. In addition to the ferric ion, in fact, more than 20 different metal complexes of deferoxamine b have been characterized in terms of their chemical speciation in solution. In addition, the availability of a terminal amino group, most often not involved in complexation, opens the way to deferoxamine B modification and functionalization. This review aims to collect and summarize the available data concerning the complex-formation equilibria in solutions of deferoxamine B with different metal ions. A general overview of the progress of its applications over the past decade is also discussed, including the treatment of iron overload-associated diseases, its clinical use against cancer and neurodegenerative disorders and its role as a diagnostic tool.

scholarly journals MRI evaluation of hepatic and cardiac iron burden in pediatric thalassemia major patients: spectrum of findings by T2*

2019 ◽  
Vol 50 (1) ◽  
Author(s):  
Samar M. Shehata ◽  
Mohamed I. Amin ◽  
El Sayed H. Zidan
Keyword(s):  
Chelation Therapy ◽  
Statistical Significance ◽  
Iron Chelation ◽  
Good Method ◽  
Thalassemia Major ◽  
Local Magnetic Field ◽  
Cardiac Complications ◽  
Liver Iron ◽  
Cross Sectional ◽  
Signal Decay

Abstract Background Iron deposition distorts the local magnetic field exerting T2* signal decay. Biopsy, serum ferritin, echocardiography are not reliable to adjust iron chelation therapy. Quantified MRI signal decay can replace biopsy to diagnose iron burden, guide treatment, and follow up. The objective of this study is to evaluate the role of T2* in quantification of the liver and heart iron burden in thalassemia major patients. This cross-sectional study included 44 thalassemia patients who were referred to MRI unit, underwent T2* MRI. Results Twenty-one male (47.7%) and 23 female (52.3%) were included (age range 6–15 years, mean age 10.9 ± 2.9 years). Patients with excess hepatic iron show the following: 11/40 (27.5%) mild, (13/40) 32.5% moderate, and (14/40) 35% severe liver iron overload. High statistical significance regarding association between LIC and liver T2* (p = 0.000) encountered. Cardiac T2* values showed no relationship with age (p = 0.6). Conclusion T2* is a good method to quantify, monitor hepatic and myocardial iron burden, guiding chelation therapy and prevent iron-induced cardiac complications.

scholarly journals Correction to: Changes in inflammatory cytokines, antioxidants and liver stiffness after chelation therapy in individuals with chronic lead poisoning

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Tongluk Teerasarntipan ◽  
Roongruedee Chaiteerakij ◽  
Piyapan Prueksapanich ◽  
Duangporn Werawatganon
Keyword(s):  
Inflammatory Cytokines ◽  
Lead Poisoning ◽  
Chelation Therapy ◽  
Liver Stiffness

An amendment to this paper has been published and can be accessed via the original article.

Sign in / Sign up

Export Citation Format

Share Document